Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | ALB | P02768 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | TK1 | P04183 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21277447 | 0.90 | TK1 (0.43) | LMNAALBALDH1A1BLMPOLB | |
| SCHEMBL21277437 | 0.90 | TK1 (0.43) | LMNAALBALDH1A1BLMPOLB | |
| SCHEMBL925743 | 0.86 | LMNA (0.58) | LMNAALBALDH1A1BLMPOLB | |
| SCHEMBL14596607 | 0.86 | LMNA (0.58) | LMNAALBALDH1A1BLMPOLB | |
| SCHEMBL14421795 | 0.86 | LMNA (0.58) | LMNAALBALDH1A1BLMPOLB | |
| SCHEMBL23485 | 0.86 | LMNA (0.58) | LMNAALBALDH1A1BLMPOLB | |
| SCHEMBL22992337 | 0.86 | LMNA (0.58) | LMNAALBALDH1A1BLMPOLB | |
| SCHEMBL762579 | 0.86 | LMNA (0.58) | LMNAALBALDH1A1BLMPOLB | |
| SCHEMBL13286394 | 0.86 | LMNA (0.58) | LMNAALBALDH1A1BLMPOLB | |
| SCHEMBL29711774 | 0.86 | LMNA (0.58) | LMNAALBALDH1A1BLMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025262186-A2 | THERAPEUTIC OLIGONUCLEOTIDES FOR TREATING DISEASES BEING ASSOCIATED WITH OR CAUSED BY A MISSENSE, NONSENSE OR IN-FRAME INDEL MUTATION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-12-26 | — | — | WO | claimed |
| WO-2025069117-A1 | METHOD FOR HIGHLY SENSITIVE ANALYTES DETECTION | ULISSE BIOMED S.P.A. (IT) | 2025-04-03 | — | — | WO | claimed |
| WO-2025024123-A1 | NOVEL CITICOLINE DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-30 | — | — | WO | claimed |
| EP-3452601-B1 | CELL-FREE PROTEIN EXPRESSION USING ROLLING CIRCLE AMPLIFICATION PRODUCT | Global Life Sciences Solutions Operations UK Ltd (GB) | 2024-10-16 | — | — | EP | claimed |
| EP-3684934-B1 | IN VIVO RNA OR PROTEIN EXPRESSION USING DOUBLE-STRANDED CONCATEMERIC DNA INCLUDING PHOSPHOROTHIOATED NUCLEOTIDES | Global Life Sciences Solutions Operations UK Ltd (GB) | 2024-06-19 | — | — | EP | claimed |
| CN-111094574-B | In vivo RNA or protein expression using double stranded concatemer DNA comprising phosphorothioated nucleotides | 环球生命科学解决方案运营英国有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-110997922-B | Cell-free protein expression using double-stranded concatemer DNA | 环球生命科学解决方案运营英国有限公司 | 2024-04-16 | — | — | CN | claimed |
| EP-3371326-B1 | LIGASE-ASSISTED NUCLEIC ACID CIRCULARIZATION AND AMPLIFICATION | Global Life Sciences Solutions Operations UK Ltd (GB) | 2023-11-01 | — | — | EP | claimed |
| EP-3665286-B1 | CELL-FREE PROTEIN EXPRESSION USING DOUBLE-STRANDED CONCATAMERIC DNA | Global Life Sciences Solutions Operations UK Ltd (GB) | 2023-09-13 | — | — | EP | claimed |
| US-20220389473-A1 | CELL-FREE PROTEIN EXPRESSION USING ROLLING CIRCLE AMPLIFICATION PRODUCT | GLOBAL LIFE SCIENCES SOLUTIONS OPERATIONS UK LIMITED (GB) | 2022-12-08 | — | — | US | claimed |
| US-20170121747-A1 | ISOTHERMAL AMPLIFICATION UNDER LOW SALT CONDITION | Global Life Sciences Solutions Operations UK Ltd (GB) | 2017-05-04 | — | — | US | claimed |
| US-9587263-B2 | Isothermal amplification under low salt condition | GENERAL ELECTRIC COMPANY (US) | 2017-03-07 | — | — | US | claimed |
| EP-3122888-A2 | ISOTHERMAL AMPLIFICATION UNDER LOW SALT CONDITION | General Electric Company (US) | 2017-02-01 | — | — | EP | claimed |
| US-9353393-B2 | Methods and kits for reducing non-specific nucleic acid amplification | GENERAL ELECTRIC COMPANY (US) | 2016-05-31 | — | — | US | claimed |
| US-20160053307-A1 | LIGASE-ASSISTED NUCLEIC ACID CIRCULARIZATION AND AMPLIFICATION | Global Life Sciences Solutions Operations UK Ltd (GB) | 2016-02-25 | — | — | US | claimed |
| WO-2015148218-A2 | ISOTHERMAL AMPLIFICATION UNDER LOW SALT CONDITION | GENERAL ELECTRIC COMPANY (US) | 2015-10-01 | — | — | WO | claimed |
| US-20150275282-A1 | ISOTHERMAL AMPLIFICATION UNDER LOW SALT CONDITION | GENERAL ELECTRIC COMPANY (US) | 2015-10-01 | — | — | US | claimed |
| EP-2814976-A1 | METHODS AND KITS FOR REDUCING NON-SPECIFIC NUCLEIC ACID AMPLIFICATION | General Electric Company (US) | 2014-12-24 | — | — | EP | claimed |
| WO-2013123187-A1 | METHODS AND KITS FOR REDUCING NON-SPECIFIC NUCLEIC ACID AMPLIFICATION | GENERAL ELECTRIC COMPANY (US) | 2013-08-22 | — | — | WO | claimed |
| US-20130210078-A1 | METHODS AND KITS FOR REDUCING NON-SPECIFIC NUCLEIC ACID AMPLIFICATION | GENERAL ELECTRIC COMPANY (US) | 2013-08-15 | — | — | US | claimed |